Pharma Focus Europe

RS BioTherapeutics and University of Colorado School of Medicine Announce Research Collaboration

Monday, July 08, 2024

RS BioTherapeutics has entered into a collaboration with the University of Colorado School of Medicine to evaluate their novel steroid-free therapeutic platform, RSBT-001, for treating lethal lung diseases characterized by pulmonary inflammation. The collaboration also aims to investigate RSBT-001's potential as a chemical countermeasure.

This partnership is specifically with Dr. Tom Hu's laboratory, part of the Division of Pulmonary and Sleep Medicine at the University of Colorado School of Medicine. Dr. Hu, who joined the university in 2023 after a distinguished career in federal service, brings extensive expertise in chemical, biological, radiological, and nuclear (CBRN) countermeasures, having served at the Biomedical Advanced Research and Development Authority (BARDA).

RS BioTherapeutics, expressed enthusiasm about collaborating with Dr. Hu's lab, highlighting his academic credentials and broad experience in academia and government as crucial for evaluating RSBT-001's potential applications.

Dr. Hu emphasized that RSBT-001 is currently being developed for Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF), citing its anti-inflammatory properties demonstrated in preclinical trials. He expressed excitement about working with RS BioTherapeutics to advance the development of RSBT-001, particularly its potential as a chemical countermeasure.

This collaboration leverages the University of Colorado School of Medicine's expertise in pulmonary and critical care medicine, aiming to advance innovative treatments for severe lung diseases and enhance readiness against chemical threats.

 

Source: globenewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva